Landscape Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Landscape Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-2,816	Closed	-$564K	–	846
2022 Q3	$564K	Buy	+2,816	New	+$537K	0.07%	266
2019 Q3	–	Sell	-14,145	Closed	-$1.03M	–	635
2019 Q2	$1.03M	Hold	14,145	–	–	0.08%	269
2019 Q1	$1.32M	Sell	14,145 -744	-5%	-$62.2K	0.13%	191
2018 Q4	$1.09M	Buy	+14,889	New	+$1.15M	0.09%	233
2017 Q1	–	Sell	-11,154	Closed	-$418K	–	502
2016 Q4	$418K	Buy	+11,154	New	+$467K	0.06%	352
2015 Q3	–	Sell	-4,300	Closed	-$515K	–	628
2015 Q2	$515K	Buy	+4,300	New	+$514K	0.09%	323

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Landscape Capital Management's ALNY Position: Q4 2022 in Review

Landscape Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 2,816 shares — an estimated $564K sold.

Landscape Capital Management first reported a position in ALNY in Q2 2015 and held it in 6 quarters. The position peaked at $1.32M in Q1 2019. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

Landscape Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Landscape Capital Management sold 2,816 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $564K.
Landscape Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2015 and held it in 6 quarters.
Landscape Capital Management's Alnylam Pharmaceuticals position peaked at $1.32M in Q1 2019.
487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Landscape Capital Management's 13F filing for Q4 2022, filed 9 Feb 2023.